U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06884982) titled 'An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib' on March 13.
Brief Summary: This is a single-center, single-arm, prospective trial to explore the efficacy and safety of neoadjuvant treatment with Iparomlimab and Tuvonralimab Injection combined with lenvatinib in patients with advanced HCC
Study Start Date: March 13
Study Type: INTERVENTIONAL
Condition:
HCC - Hepatocellular Carcinoma
Intervention:
DRUG: QL1706 Plus Lenvatinib
All enrolled subjects will receive QL1706 5 mg/kg intravenously plus lenvatinib 8/12mg on day 1 of each cycle (every 3 weeks). Tum...